NCT02773030 2024-06-25A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple MyelomaCelgenePhase 1/2 Active not recruiting466 enrolled